TIMP3 Overexpression in Macrophages Protects From Insulin Resistance, Adipose Inflammation, and Nonalcoholic Fatty Liver Disease in Mice
Inflammation
Tissue Inhibitor of Metalloproteinase-3
0301 basic medicine
570
Macrophages
Settore MED/09 - MEDICINA INTERNA
610
Antigens, Differentiation, Myelomonocytic
Settore MED/49 - SCIENZE TECNICHE DIETETICHE APPLICATE
Diet, High-Fat
Pathophysiology
Fatty Liver
Mice
03 medical and health sciences
Settore BIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA
Adipose Tissue
Antigens, CD
Fluorodeoxyglucose F18
Non-alcoholic Fatty Liver Disease
Animals
Obesity
RNA, Messenger
Insulin Resistance
Adiposity
DOI:
10.2337/db11-0613
Publication Date:
2012-01-07T06:04:54Z
AUTHORS (14)
ABSTRACT
The tissue inhibitor of metalloproteinase (TIMP)3, a stromal protein that restrains the activity of proteases and receptors, is reduced in inflammatory metabolic disorders such as type 2 diabetes mellitus (T2DM) and atherosclerosis. We overexpressed Timp3 in mouse macrophages (MacT3) to analyze its potential antidiabetic and antiatherosclerotic effects. Transgenic mice with myeloid cells targeting overexpression of TIMP3 were generated and fed a high-fat diet for 20 weeks. Physical and metabolic phenotypes were determined. Inflammatory markers, lipid accumulation, and insulin sensitivity were measured in white adipose tissue (WAT), liver, and skeletal muscle. In a model of insulin resistance, MacT3 mice were more glucose tolerant and insulin sensitive than wild-type mice in both in vitro and in vivo tests. Molecular and biochemical analyses revealed that increased expression of TIMP3 restrained metabolic inflammation and stress-related pathways, including Jun NH2-terminal kinase and p38 kinase activation, in WAT and liver. TIMP3 overexpression in macrophages resulted in reduced activation of oxidative stress signals related to lipid peroxidation, protein carbonylation, and nitration in WAT and liver. Our data show that macrophage-specific overexpression of TIMP3 protects from metabolic inflammation and related metabolic disorders such as insulin resistance, glucose intolerance, and nonalcoholic steatohepatitis.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (45)
CITATIONS (67)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....